Unlocking how cellular proteins control cancer spread
A new insight into cell signals that control cancer growth and migration could help in the search for effective anti-cancer drugs. A McGill University-led study reveals key biochemical processes that advance our understanding of colorectal cancer, the third most common cancer among Canadians.
Using the Canadian Macromolecular Crystallography Facility beamline at the Canadian Light Source at the University of Saskatchewan, scientists from McGill University and Osaka University in Japan were able to unlock the behavior of an enzyme involved in the spread of cancer cells. In a study published in the Journal of Biological Chemistry, the team found that there is a delicate interaction between the enzyme, PRL3, and another protein that moves magnesium in and out of cells. This interaction is crucial to colorectal cancer growth.

"These enzymes were first seen in liver cells that were activated to start growing, so somehow they act as a growth signal," said McGill biochemistry professor and corresponding author Kalle Gehring.
It was generally believed that PRL3 proteins acted as enzymes to control cancer cells. Therefore, it came as a surprise when Gehring and his team found that a mutation that leads to a loss of the enzyme activity still maintained the same influence over cancer growth and migration. "What our new paper showed is that a second activity of PRL3, control of a magnesium transporter, is the signal that instructs the cancer to travel to other parts of the body. It was very exciting that the mutant protein that has no catalytic activity, but still binds very tightly to magnesium transport proteins, turned out to be as oncogenic as the wild-type protein," said Gehring.
The team's findings call into question long-standing hypotheses about the role PRL3 plays in the spread of cancer and indicate that the binding mechanism is somehow key.
Understanding that binding the magnesium transporters and not the enzyme's catalytic activity influences cancer growth and migration signaling is key information for identifying novel compounds to prevent cancer spread. Current drug screening against PRL3 has focused on identifying compounds that block phosphatase activity. By testing the wrong function, the screens may have missed other compounds of therapeutic interest. Shifting the focus to the enzyme's ability to bind to magnesium transporters is one way to help companies identify better therapeutics for cancer through drug screening methods.
Future work will include more detailed studies on the role of the magnesium transporter and its interactions with PRL3.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Mapping the placenta’s hormone network
Study uncovers how the placenta actively metabolizes not only glucocorticoids but also novel androgens and progesterones, reshaping our understanding of pregnancy and its complications.

Biochemists and molecular biologists sweep major 2025 honors
Recent Nobel, MacArthur and Kimberly Prize honorees highlight the power of biochemistry and molecular biology to drive discovery, including immune tolerance, vaccine design and metabolic disease, and to advance medicine and improve human health.

Spider-like proteins spin defenses to control immunity
Researchers from Utrecht University discovered two distinct binding modes of a spider-shaped immune inhibitor found in serum.

A biological camera: How AI is transforming retinal imaging
AI is helping clinicians see a more detailed view into the eye, allowing them to detect diabetic retinopathy earlier and expand access through tele-ophthalmology. These advances could help millions see a clearer future.

AI in the lab: The power of smarter questions
An assistant professor discusses AI's evolution from a buzzword to a trusted research partner. It helps streamline reviews, troubleshoot code, save time and spark ideas, but its success relies on combining AI with expertise and critical thinking.

Training AI to uncover novel antimicrobials
Antibiotic resistance kills millions, but César de la Fuente’s lab is fighting back. By pairing AI with human insight, researchers are uncovering hidden antimicrobial peptides across the tree of life with a 93% success rate against deadly pathogens.